Podium to Practice: EHA 2025 – Leukemia: LUSPATERCEPT VS EPOETIN ALFA IN THE COMMANDS TRIAL

Podium to Practice: EHA 2025 – Leukemia: LUSPATERCEPT VS EPOETIN ALFA IN THE COMMANDS TRIAL

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Julie Bergeron

Icon Chair Speaker

Speakers

Dr. Brian Leber

Dr. Danielle Hammond

Studies / Trials Discussed

S177 – OVERALL SURVIVAL AND DURATION OF TRANSFUSION INDEPENDENCE FOR FIRST-LINE ESA-NAIVE PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH LUSPATERCEPT VS EPOETIN ALFA IN THE COMMANDS TRIAL

Studies/trials discussed:

S177 – OVERALL SURVIVAL AND DURATION OF TRANSFUSION INDEPENDENCE FOR FIRST-LINE ESA-NAIVE PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH LUSPATERCEPT VS EPOETIN ALFA IN THE COMMANDS TRIAL
Tagged